| Describes the development of humanized mouse model of MYC/BCL2-driven _double-hit_ lymphoma. By engrafting human HSCs transduced with the oncogene combination into immunodeficient mice, we generate a fatal B malignancy with complete penetrance | lymphoma, |
| Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. | lymphoma, |
| Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. | breast, |
| Data suggest that up-regulation of Bcl-2 (bcl-2 proto-oncogene protein) is directly regulated by NFkappaB during apoptosis of breast cancer cells in response to tumor necrosis factor-alpha; induction of Bcl-2 is mediated by p65 subunit of NFkappaB. | breast, |
| Correlation of nuclear morphometry of primary melanoma of the skin with clinicopathological parameters and expression of tumor suppressor proteins (p53 and p16(INK4a)) and bcl-2 oncoprotein. | skin, |
| MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. | colorectal, |
| Apoptosis and cell proliferation: correlation with BCL-2 and P53 oncoprotein expression in human hepatocellular carcinoma. | liver, |
| Apoptosis and cell proliferation: correlation with BCL-2 and P53 oncoprotein expression in human hepatocellular carcinoma. | liver, |
| Data indicate that diffuse large B-cell lymphoma (DLBCL) patients with proto-oncogene proteins MYC or BCL2 copy number aberration (CNA) constituted a unique group with extremely poor outcome and may require more aggressive treatment regimens. | lymphoma, |
| A search for bcl1, bcl2, and c-myc oncogene rearrangements in chronic lymphocytic leukemia. | leukemia, |
| Data confirmed the validity of the RC cell line as a representative model of proto-oncogene proteins MYC/BCL2 double-hit diffuse large B cell lymphoma. | lymphoma, |
| The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation. | lymphoma, |
| High BCL2 expression is associated with oncogenicity and chemoresistance in hepatocellular carcinoma. | liver, |
| Data suggest that neuroprotection via ghrelin involves up-regulation of Bcl-2 (B cell lymphoma 2 associated oncogene) and p-62/Sqstm1 (ubiquitin-binding protein p62) plus down-regulation of LC3-II (microtubule-associated protein 1 light chain 3) and Beclin-1. Studies were conducted in adult hippocampal neural stem cells in primary culture. | lymphoma, |
| Bcl-2 oncoprotein is widespread in lymphoid tissue and lymphomas but its differential expression in benign versus malignant follicles and monocytoid B-cell proliferations is of diagnostic value. | lymphoma, |
| Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. | lung, |
| Apoptosis and expression of the bcl-2 proto-oncogene in the fetal and adult human kidney: evidence for the contribution of bcl-2 expression to renal carcinogenesis. | kidney, |
| High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. | leukemia, |
| High expression of latent membrane protein 1 of Epstein-Barr virus and BCL-2 oncoprotein in acquired immunodeficiency syndrome-related primary brain lymphomas. | lymphoma,brain, |
| Bcl-2 oncoprotein expression in acute myeloid leukemia. | leukemia, |